Lung cancer patients to get breakthrough drug sotorasib on NHS

Sotorasib, the first treatment of its kind, binds with the KRAS G12C mutation and makes it inactive, stopping cell division and cancer growth. Around 600 patients a year will be given the drug initially in England, starting within weeks, following a national access agreement.

SPS commentary:

NHS England, NICE and Amgen have reached an agreement to enable early access to sotorasib for eligible lung cancer patients in England on a budget-neutral basis to the NHS while NICE completes its ongoing appraisal.

This is the second Orbis-licenced drug the NHS has made available through a national access agreement. Project Orbis is an international partnership between medicines regulators in the UK, U.S., Australia and others, set up to speed up the approval process for promising cancer treatments.

Sotorasib will be used in patients with the KRAS G12C mutation that occurs in about 13% of non-small cell lung cancers.

NHS England